MD — Pediatrix Medical Group, Inc.

Summary of Pediatrix Medical Group Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Adjusted EBITDA: $58 million for Q1 2026.
• Revenue Growth: Consolidated revenue increased due to a 3% growth in same unit activity and $6 million from net non-same unit activity, despite a modest decline in same unit volumes.
• Pricing Growth: Achieved a 4% increase in pricing, driven by strong revenue cycle management (RCM) cash collections, contract administrative fees, favorable payer mix, and increased patient acuity in neonatology.
• Operating Cash Flow: Utilized $130 million in operating cash flow, up from $116 million year-over-year, primarily due to incentive compensation payments.
• Capital Deployment: Invested $21 million to repurchase 1 million shares, leaving 82 million shares outstanding.
• Debt Metrics: Ended the quarter with over $385 million in net debt, reflecting a net leverage ratio of approximately 1.3x based on the midpoint of the adjusted EBITDA outlook for 2026.

2. Strategic Updates and Business Highlights

• Leadership Additions: Welcomed Dr. Jim Barry and Dr. Jochen Profit to enhance clinical quality and transformation efforts.
• Quality Focus: Emphasized investments in care quality, with a commitment to outperforming competitors and improving patient outcomes.
• Expansion Opportunities: Highlighted potential growth in teleservices and partnerships with hospitals, leveraging a strong balance sheet for strategic acquisitions.
• Compensation Program: Successfully integrated share price-based awards into the compensation structure, with 45 clinician leaders joining as Pediatrix partners.

3. Forward Guidance and Outlook

• Full-Year EBITDA Outlook: Reaffirmed guidance for adjusted EBITDA in the range of $280 million to $300 million for 2026, expecting Q1 results to represent about 20% of this annual target.
• Pricing Expectations: While pricing growth was strong in Q1, management anticipates a potential decline in pricing momentum in the latter half of the year, maintaining a flat pricing outlook for 2026.

4. Challenges and Points of Concern

• Volume Declines: Noted a modest decline in same unit volumes, particularly in NICU days, although recent trends do not show a continuation of this decline.
• Market Pressures: Acknowledged that major hospital systems are experiencing revenue and patient volume declines, which could impact Pediatrix in the future.
• Uncertainty Around Subsidies: Potential headwinds from the lapse of tax subsidies remain uncertain, though management is currently not factoring this into their forecasts.

5. Notable Q&A Insights

• Pricing Drivers: Management confirmed that approximately 25% of Q1 pricing growth was attributed to RCM cash collections, with expectations of a tapering effect in the second half of the year.
• Payer Mix Stability: Despite broader market pressures, management reported no signs of weakness in payer mix or demand, maintaining a positive outlook for their services.
• Acquisition Performance: Recent acquisitions have exceeded initial projections, contributing positively to overall performance.
• Contract Revenue Dynamics: Discussed the complexity of contract revenue and salary increases, emphasizing the need for hospital support for salary adjustments.

Overall, Pediatrix Medical Group reported solid financial results in Q1 2026, with strategic investments in quality and leadership, while navigating potential market challenges and maintaining a cautious outlook for the remainder of the year.